Vertex Pharmaceuticals 통합
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionMarshall Wace, Llp
Latest Disclosed Ownership317,058 shares
Latest Disclosed Value $ 141,579,080
Marshall Wace, Llp ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 14, 2026 - Marshall Wace, Llp filed a 13F-HR form disclosing ownership of 317,058 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $141,579,079 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 204,032 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 55.40% during the quarter. The current value of the position is $141,671,026 USD.

Marshall Wace, Llp has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 2,000 of underlying shares valued at $893,080 USD and put options representing 4,500 of underlying shares valued at $2,009,430 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 317,058 113,026 55.40 141,579 53.06 0.0668
2026-02-13 2025-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 204,032 158,147 344.66 92,500 414.74 0.0842
2025-11-13 2025-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 45,885 -71,115 -60.78 17,970 -65.50 0.0182
2025-08-13 2025-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 117,000 -21,000 -15.22 52,088 -22.15 0.0587
2025-05-15 2025-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 138,000 -56,000 -28.87 66,905 -14.36 0.0849
2025-02-13 2024-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 194,000 -50,000 -20.49 78,124 -31.16 0.0939
2024-11-14 2024-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 244,000 117,000 92.13 113,480 90.63 0.1382
2024-08-14 2024-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 127,000 -60,139 -32.14 59,527 -23.90 0.0795
2024-05-15 2024-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 187,139 -91,191 -32.76 78,226 -30.93 0.1191
2024-02-14 2023-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 278,330 72,715 35.36 113,250 58.39 0.1918
2023-11-14 2023-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 205,615 25,815 14.36 71,501 13.00 0.1448
2023-08-14 2023-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 179,800 -213,329 -54.26 63,273 -48.92 0.1236
2023-05-15 2023-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 393,129 -16,892 -4.12 123,863 4.61 0.2632
2023-02-14 2022-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 410,021 136,169 49.72 118,406 49.33 0.2663
2022-11-14 2022-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 273,852 -117,300 -29.99 79,291 -28.06 0.1737
2022-08-15 2022-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 391,152 391,152 110,223 0.2268
2022-05-16 2022-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 0 -150,000 -100.00 0 -100.00
2022-02-14 2021-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 150,000 -406,678 -73.05 32,940 -67.38 0.0608
2021-11-15 2021-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 556,678 5,719 1.04 100,975 -9.11 0.4193
2021-08-13 2021-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 550,959 364,231 195.06 111,090 176.85 0.5412
2021-05-17 2021-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 186,728 -12,859 -6.44 40,127 -14.93 0.1840
2021-02-16 2020-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 199,587 158,119 381.30 47,171 318.07 0.2556
2020-11-16 2020-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 41,468 36,846 797.19 11,283 740.76 0.0722
2020-08-13 2020-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 4,622 3,982 622.19 1,342 782.89 0.0094
2020-05-15 2020-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 640 -36,885 -98.29 152 -98.15 0.0015
2020-02-14 2019-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 37,525 -36,033 -48.99 8,216 -34.07 0.0565
2019-11-14 2019-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 73,558 -18,727 -20.29 12,462 -26.36 0.0980
2019-08-14 2019-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 92,285 30,053 48.29 16,924 47.85 0.1392
2019-05-29 2019-03-31 13F/A-1 VERTEX PHARM COMMON STOCK 92532F100 62,232 672 1.09 11,447 12.21 0.1076
2019-05-14 2019-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 62,232 672 11,447
2019-02-14 2018-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 61,560 -123,252 -66.69 10,201 -71.36 0.1041
2018-12-06 2018-09-30 13F/A-1 VERTEX PHARM COMMON STOCK 92532F100 184,812 -191,673 -50.91 35,621 -44.33 0.3030
2018-11-14 2018-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 184,812 -191,673 35,621
2018-08-14 2018-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 376,485 343,094 1,027.50 63,987 1,075.80 0.9574
2018-05-15 2018-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 33,391 -77,273 -69.83 5,442 -67.19 0.2256
2018-03-29 2017-12-31 13F/A-1 VERTEX PHARM COMMON STOCK 92532F100 110,664 89,097 413.12 16,584 405.92 0.6969
2018-02-14 2017-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 110,664 89,097 16,584
2017-11-13 2017-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 21,567 -27,265 -55.83 3,278 -47.96 0.1524
2017-08-04 2017-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 48,832 48,832 126.42 6,299 92.16 0.2774
2016-05-13 2016-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 0 -241,824 -100.00 0 -100.00
2016-02-10 2015-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 241,824 148,314 158.61 30,428 212.47 0.2855
2015-11-12 2015-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 93,510 68,725 277.28 9,738 218.24 0.1196
2015-08-14 2015-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 24,785 -151,451 -85.94 3,060 -85.28 0.0399
2015-05-11 2015-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 176,236 -239,875 -57.65 20,790 -57.94 0.2709
2015-02-17 2014-12-31 13F VERTEX PHARM COMMON STOCK 92532F100 416,111 416,111 136.11 49,434 137.78 0.6526
2014-11-13 2014-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 0 -3,290 -100.00 0 -100.00
2014-08-14 2014-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 3,290 3,290 311 0.0046
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-14 2026-03-31 13F VERTEX PHARM EQUITY OPTION Call 2,000 66.67 893 64.15 n/a n/a n/a
2026-02-13 2025-12-31 13F VERTEX PHARM EQUITY OPTION Call 1,200 50.00 544 73.80 n/a n/a n/a
2025-11-13 2025-09-30 13F VERTEX PHARM EQUITY OPTION Call 800 313 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-14 2026-03-31 13F VERTEX PHARM EQUITY OPTION Put 4,500 1,025.00 2,009 1,009.94 n/a n/a n/a
2026-02-13 2025-12-31 13F VERTEX PHARM EQUITY OPTION Put 400 100.00 181 132.05 n/a n/a n/a
2025-11-13 2025-09-30 13F VERTEX PHARM EQUITY OPTION Put 200 78 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.